Literature DB >> 10235483

Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.

G Ragupathi1, L Howard, S Cappello, R R Koganty, D Qiu, B M Longenecker, M A Reddish, K O Lloyd, P O Livingston.   

Abstract

Sialyl-Tn (STn) is an O-serine- or O-threonine-linked disaccharide [NeuAcalpha(2-->6)GalNAcalpha-O-Ser/Thr) expressed on mucins of most types of adenocarcinoma as single STn or clustered STn [STn(c)] epitopes. Though STn is expressed on some normal tissues it is relatively tumor-specific, especially in the clustered conformation. Clinical trials with STn-keyhole limpet hemocyanin (KLH) conjugate vaccines, prepared using reductive amination with a two-carbon linker group, have resulted in high titers against STn but lower titers against natural forms of STn (ovine submaxillary mucin, or tumor cells). To obtain antibodies of more appropriate specificity, we attempted to prepare STn(c)-KLH conjugates to establish their immunogenicity in mice in preparation for clinical trials; however, conjugation efficiency was poor when the same two-carbon linker was used, presumably because of steric hindrance. STn-KLH and STn(c)-KLH conjugates were prepared using the regular two-carbon or the recently developed more efficient longer heterobifunctional 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide (MMCCH) linkers, and the resulting immunogenicities in mice were compared. The highest titers against STn were seen with the STn-KLH conjugate with the two-carbon linker, and the highest titers against STn(c) were seen with STn(c)-KLH with the MMCCH linker. Conjugation with MMCCH resulted in the highest conjugation efficiency (yield) and the highest titers against ovine submaxillary mucin and STn-positive tumor cells, and is the method of choice for the preparation of STn(c) vaccine for clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10235483     DOI: 10.1007/s002620050542

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

Review 1.  Synthetic multivalent ligands as probes of signal transduction.

Authors:  Laura L Kiessling; Jason E Gestwicki; Laura E Strong
Journal:  Angew Chem Int Ed Engl       Date:  2006-04-03       Impact factor: 15.336

2.  Toward optimized carbohydrate-based anticancer vaccines: epitope clustering, carrier structure, and adjuvant all influence antibody responses to Lewis(y) conjugates in mice.

Authors:  V Kudryashov; P W Glunz; L J Williams; S Hintermann; S J Danishefsky; K O Lloyd
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

3.  Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Authors:  Z G Wang; L J Williams; X F Zhang; A Zatorski; V Kudryashov; G Ragupathi; M Spassova; W Bornmann; S F Slovin; H I Scher; P O Livingston; K O Lloyd; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

4.  Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide.

Authors:  Pamela Thompson; Vani Lakshminarayanan; Nitin T Supekar; Judy M Bradley; Peter A Cohen; Margreet A Wolfert; Sandra J Gendler; Geert-Jan Boons
Journal:  Chem Commun (Camb)       Date:  2015-05-29       Impact factor: 6.222

5.  Recent Development in Carbohydrate Based Anti-cancer Vaccines.

Authors:  Zhaojun Yin; Xuefei Huang
Journal:  J Carbohydr Chem       Date:  2012-02-29       Impact factor: 1.667

6.  Glycosylations versus conformational preferences of cancer associated mucin core.

Authors:  J Schuman; D Qiu; R R Koganty; B M Longenecker; A P Campbell
Journal:  Glycoconj J       Date:  2000-12       Impact factor: 2.916

7.  Improving the antigenicity of sTn antigen by modification of its sialic acid residue for development of glycoconjugate cancer vaccines.

Authors:  Jian Wu; Zhongwu Guo
Journal:  Bioconjug Chem       Date:  2006 Nov-Dec       Impact factor: 4.774

8.  Synthetic and immunological studies of 5'-N-phenylacetyl sTn to develop carbohydrate-based cancer vaccines and to explore the impacts of linkage between carbohydrate antigens and carrier proteins.

Authors:  Qianli Wang; Sandamali Amarasingha Ekanayaka; Jian Wu; Junping Zhang; Zhongwu Guo
Journal:  Bioconjug Chem       Date:  2008-09-25       Impact factor: 4.774

9.  Imparting bone affinity to glycoproteins through the conjugation of bisphosphonates.

Authors:  Sébastien A Gittens; John R Matyas; Ronald F Zernicke; Hasan Uludağ
Journal:  Pharm Res       Date:  2003-07       Impact factor: 4.200

10.  Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197.

Authors:  Fatme Mawas; Jutta Niggemann; Christopher Jones; Michael J Corbel; Johannis P Kamerling; Johannes F G Vliegenthart
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.